Comparative evaluation of immunogenicity of pneumococcal conjugate vaccine in two strains of BALB/c and DBA/2 mice : Preclinical study

Subject Areas : Veterinary Clinical Pathology

ramin farhoudi ¹ (Assistant Professor, Department of Quality Control, Pasteur Institute of Iran, Tehran, Iran.)
delaram doroud ² (Assistant Professor, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.)
GOLSHID javdani ³ (Assistant Professor, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.)
mohammad hosin hedayati ⁴ (Ph.D. Graduate, Department of Quality Control, Pasteur Institute of Iran, Tehran, Iran.)

Received: 2022-02-02 Accepted : 2022-06-01 Published : 2022-05-22

Keywords: horse, Vaccine, Flowcytometry, Streptococcus pneumoniae,

Abstract :

Streptococcus pneumoniae is easily transmitted from humans to animals and causes pneumonia, especially in horses. Extensive human vaccination prevents the transmission of the disease to the horse host. The immunogenicity of a vaccine is evaluated by various methods. The aim of this study was to design a test to evaluate the immunogenicity of pneumococcal conjugate vaccine as part of pre-clinical studies of vaccine production. After culturing Streptococcus pneumoniae serotype 19F in blood agar medium, the obtained colonies were labeled using fluorescence dye. On the other hand, the serum of BALB/c and DBA/2 mice immunized with Pneumococcal Conjugate Vaccine was collected to determine antibodies with phagocytosis properties against Streptococcus pneumoniae. After proximity of serum dilutions with labeled bacteria, the ability of bacteria to phagocytosis by serum opsonins (opsonophagocytosis) was read by adding mouse macrophage cells by flow cytometry. In both strains, the percentage of cells in the serum that phagocytosed the bacterium decreased with decreasing serum dilution. Opsonophagocytic titers were reported 128 in BALB/c mice and 64 in DBA/2 mice. On the other hand, flow cytometry results were significantly different from the results of manual colony count test (r = 0.89, p≤0.001). According to the results of the present study, the BALB/c strain of mice was a better host to determine the efficacy of the vaccine. Also, using flow cytometry method has more advantages than manual assay method. As a result, the data of this study bring us one step closer to producing an effective vaccine.

References:

• Berical, A.C., Harris, D., Dela Cruz, C.S. and Possick, J.D. (2016). Pneumococcal Vaccination Strategies an Update and Perspective. Annals of American Thoracic Society, 13(6): 933-944.


• Borsa, N., Pasquale, M.D. and Restrepo, M.I. (2019). Animal Models of pneumococcal pneumonia. International Journal of Molecular Science, 20(17): 4222.


• Chanter, N. (1997). Streptococci and enterococci as animal pathogens. Journal of Applied Microbiology Symposium Supplement, 83(S1): 100S-109S.


• Chiavolini, D., Pozzi, G. and Ricci, S. (2008). Animal models of Streptococcus pneumonia Disease. Clinical Microbiology Reviews, 21(4): 666-685.


• Converso, T.R., Assoni, L., André, G.O., Darrieux, M. and Leite, L.C.C. (2020). The long search for a serotype independent pneumococcal vaccine. Expert Review of Vaccines, 19(1): 57-70.


• Daniels, C.C., Rogers, P.D. and Shelton, C.M. (2016). Review of pneumococcal vaccines: Current polysaccharide vaccine recommendations and future protein antigenes. The Journal of Pediatric Pharmacology and Therapeutics, 21(1): 27-35.


• Dockrell, H.D., Whyte Moira, M.K.B. and Timothy, J.M. (2012). Pneumococcal pneumonia mechanisms of infection and resolution. Chest, 142(2): 482-491.


• Feldman, C. and Anderson R. (2020). Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000 Research, 7(9): F1000.


• Gestur, V., Ingileif, J., Steinn, J. and Helgi, V. (1994). Opsonization and antibodies to capsular and cell wall polysaccharide of Streptococcus pneumoniae. The Journal of Infectious Diseases, 170(3): 592-599.


• Ginders, M., Leschnik, M., Künzel, F., Kampner, D., Mikula, C., Steindl, G., et al. (2017). Characterization of Streptococcus pneumoniae isolates from Austrian companion animals and horses. Acta Veterinaria Scandinavica, 59(1): 79.


• Jia, P., Dai, S., Wu, T. and Yang, S. (2021). New approaches to anticipate the risk of reverse zoonosis, 36(7): 580-590.


• Martinez, J.E., Clutterbuck, E.A., Li, H., Romero-Steiner, S. and Carlone, G.M. (2006). Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clinical and Vaccine Immunology, 13(4): 459-466.


• Martinez, J.E., Romero-Steiner, S., Pilishvili, T., Barnard, S., Schinsky, J., Goldblatt, D., et al. (1999). A flowcytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with 23-valent pneumococcal polysaccharide vaccine. Clinical and Diagnostic Laboratory Immunology, 6(4): 581-586.


• Masomian, M., Ahmad, Z., Gew, L.T. and Poh, C.L. (2020). Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines (Basel), 17; 8(1): 132.


• Nau, R., Kaye, K., Sachdeva, M., Sande, E. and Tauber, M.G. (1994). Rifampin for therapy of experimental pneumococcal meningitis in rabbits. Antimicrobial Agents and Chemotherapy, 38: 1186-1189.


• Papadatou, I., Tzovara, I. and Licciardi, P.V. (2019). The role of serotype-specific immunological memory in pneumococcal vaccination: Current knowledge and future prospects. Vaccines, 7(1): 13.


• Park, C., Kwon, E.Y., Choi, S.M., Cho, S.Y., Byun, J.H., Park, J.Y., et al. (2017). Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model. Human Vaccines & Immunotherapeutics, 13(5): 1169-1176.


• Robert, L.B. and Moon, H.N. (2006). Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clinical and Vaccine Immunology, 13(9): 1004-1009.


• Romero-Steiner, S., Frasch, C., Concepcion, N., Goldblatt, D., Kayhty, H., Vakevainen, M., et al. (2003). Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clinical and Diagnostic Laboratory Immunology, 10(6): 415-422.


• Saeland, E., Vidarsson, G. and Jonsdottir, I. (2000). Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microbial Pathogenesis, 29(2): 81-91.


• Soheyli, Z., Soleimani, M. and Majidzadeh, K. (2017). A PCR Assay for detection of mycoplasma contamination in cell culture by rRNA 16S specific primers. Paramedical Sciences and Military Health, 12(2): 13-20. [In Persian]


• Sorensen, R.U. and Edgar, D. (2019). Specific antibody deficiencies in clinical practice. The Journal of Allergy and Clinical Immunology: In Practice, 7(3): 801-808.


• Stern, P.L. (2020). Key steps in vaccine development. Annals of Allergy, Asthma & Immunology, 125(1): 17-27.


• Timoney, J.F. (2004). The pathogenic equine streptococci. Veterinary Research, 35(4): 397-409.


• Turner, A.E.B., Gerson, J.E., So, H.Y., Krasznai, D.J., Hilaire, A.J.S. and Gerson, D.F. (2017). Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumonia. Synthetic and Systems Biotechnology, 2(1): 49-58.


• Whatmore, A.M., King, S.J., Doherty, N.C., Sturgeon, D., Chanter, N. and Dowson, C.G. (1999). Molecular characterization of equine isolates of Streptococcus pneumoniae: natural disruption of genes encoding the virulence factors pneumolysin and autolysin. Infection and Immunity, 67(6): 2776-2782.


• Woudenberg, I.A., Hoenderop, J.Y. and Michel, M.F. (1979). Efficacy of antimicrobial chemotherapy in experimental rat pneumonia: effects of impaired phagocytosis. Infection and Immunity Journal, 25(1): 366-375.